948 results on '"Smith, Ian E."'
Search Results
2. HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
3. Preventing late recurrence in hormone receptor-positive early breast cancer: a review
4. Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience
5. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
6. Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.
7. Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
8. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
9. Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience
10. Trends and Variation in Issuance of High-Cost Narcolepsy Drugs by NHS England Organisations and Regions from 2019-2022
11. Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
12. Rapid Application Evolution and Integration Through Document Metamorphosis
13. De-escalating and escalating systemic therapy of early breast cancer
14. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
15. Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
16. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
17. Supplementary Table 1 from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial
18. Data from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial
19. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
20. Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer
21. Supplementary Figure from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
22. Supplementary Table S3 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
23. Supplementary methods from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
24. Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
25. Supplementary Figure 6 from Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
26. Supplementary Data from A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
27. Supplementary Table 1 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
28. Supplementary Figures from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
29. Supplementary Figure 1 from Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
30. Data from Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer
31. Supplementary Table 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
32. Supplementary Methods from Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
33. Supplementary Data from Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer
34. Supplementary Table 2 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
35. Data from A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
36. Supplementary Data from Intratumoral Estrogen Disposition in Breast Cancer
37. Supplementary Figure 2 from Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
38. Supplementary Figure 1 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
39. Supplementary Figure Legend from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
40. Supplementary Tables from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
41. Supplementary Figure 5 from Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
42. Supplementary Table 4 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
43. Supplementary Figure 3 from Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
44. Supplementary Table 5 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
45. Supplementary Figure 2 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
46. Supplementary Figure 4 from Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
47. Supplementary Figure 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
48. SUPPLEMENTARY FIGURE AND TABLE LEGENDS from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
49. Management of breast cancer in older and frail patients
50. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.